Treatment of advanced ovarian cancer with polyinosinic-polycytidylic lysine carboxymethylcellulose (poly(ICLC)).
Eight patients with advanced ovarian cancer were treated with polyinosinic-polycytidylic lysine carboxymethylcellulose (poly(ICLC]. Toxicity was substantial. No responses were seen in this small group of patients. Further clinical trials utilizing poly(ICLC) at the doses described in patients with advanced ovarian cancer do not appear to be warranted.
D000328:Adult; D000368:Aged; D002266:Carboxymethylcellulose Sodium / Q000009:adverse effects / Q000627:therapeutic use* / Q000031:analogs & derivatives; D005260:Female; D006801:Humans; D008747:Methylcellulose / Q000031:analogs & derivatives*; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000188:drug therapy*; D010865:Pilot Projects; D011070:Poly I-C / Q000009:adverse effects / Q000627:therapeutic use*; D011107:Polylysine / Q000009:adverse effects / Q000627:therapeutic use* / Q000031:analogs & derivatives
D011107:Polylysine; C019531:poly ICLC; D008747:Methylcellulose; D002266:Carboxymethylcellulose Sodium; D011070:Poly I-C